Tenatumomab
Based on 1 Customer Validation
Tenatumomab (ST2146) is a murine monoclonal antibody against tenascin-C. And tenascin-C, the large extracellular glycoprotein, is overexpressed in cancer. Tenatumomab has been used for Pretargeted Antibody Guided Radioimmunoresearch (PAGRIT), and delivering radionuclides to tumors via PAGRIT and direct 131Iodine labeling approach.
For research use only. We do not sell to patients.
- Purity: 99.29%
- CAS No.: 1412891-40-7
- Molecular Weight:147.86 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Mouse IgG2b kappa
Human
Tenascin C
Tenascin-C is a hexameric glycoprotein found in the extracellular matrix of embryos and adults. It has preferential expression in malignant solid tumors and hematologic tumors. Tenascin-C is spatially and temporally associated with tumor neovasculars and may exert anti-adhesion and immunosuppressive activities[2].
Tenatumomab (2-5 μg/mL; 16 h) retains immunoreactivity upon biotinylation. And Tenatumomab can be conjugated to up to 20 biotins per mAb,maintaining >50% immunoreactivity[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
IgG2b-kappa
ELISA, FACS, Functional assay
-
Immobilized Tenascin/Tnc protein, Human (HEK293, HY-P700833) can bind Tenatumomab, The ED50 for this effect is 6.589 ng/mL.
Chemical Information
-
CAS No. 1412891-40-7
-
Appearance Liquid
-
Molecular Weight 147.86 kDa
-
Color Colorless to light yellow
-
SMILES
[Tenatumomab]
-
Synonyms
ST2146
-
Shipping
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
-
Data Sheet (258 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
[1]. Giannini G, et al. Synthesis and preliminary in vitro evaluation of DOTA-Tenatumomab conjugates for theranostic applications in tenascin expressing tumors. Bioorg Med Chem. 2019 Aug 1;27(15):3248-3253. [Content Brief]
[2]. De Santis R, et al. Low and high tenascin-expressing tumors are efficiently targeted by ST2146 monoclonal antibody. Clin Cancer Res. 2006 Apr 1;12(7 Pt 1):2191-6. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)